FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1994271665> ?p ?o ?g. }

• W1994271665 abstract "Colorectal cancer is the third most commonly diagnosed cancer in the UK after breast and lung cancer. People with metastatic disease who are sufficiently fit are usually treated with active chemotherapy as first- or second-line therapy. Recently, targeted agents have become available including anti-epidermal growth factor receptor (EGFR) agents, for example cetuximab and panitumumab, and anti-vascular endothelial growth factor (VEGF) receptor agents, for example bevacizumab.To investigate the clinical effectiveness and cost-effectiveness of panitumumab monotherapy and cetuximab (mono- or combination chemotherapy) for Kirsten rat sarcoma (KRAS) wild-type (WT) patients, and bevacizumab in combination with non-oxaliplatin chemotherapy, for the treatment of metastatic colorectal cancer after first-line chemotherapy.The assessment comprises a systematic review of clinical effectiveness and cost-effectiveness studies, a review and critique of manufacturer submissions and a de novo cohort-based economic analysis. For the assessment of effectiveness, a literature search was conducted in a range of electronic databases, including MEDLINE, EMBASE and The Cochrane Library, from 2005 to November 2010.Studies were included if they were randomised controlled trials (RCTs) or systematic reviews of RCTs of cetuximab, bevacizumab or panitumumab in participants with EGFR-expressing metastatic colorectal cancer with KRAS WT status that has progressed after first-line chemotherapy (for cetuximab and panitumumab) or participants with metastatic colorectal cancer that has progressed after first-line chemotherapy (bevacizumab). All steps in the review were performed by one reviewer and checked independently by a second. Synthesis was mainly narrative. An economic model was developed focusing on third-line and subsequent lines of treatment. Costs and benefits were discounted at 3.5% per annum. Probabilistic and univariate deterministic sensitivity analyses were performed.The searches identified 7745 titles and abstracts. Two clinical trials (reported in 12 papers) were included. No data were available for bevacizumab in combination with non-oxaliplatin-based chemotherapy in previously treated patients. Neither of the included studies had KRAS status performed prospectively, but the studies did report retrospective analyses of the results for the KRAS WT subgroups. Third-line treatment with cetuximab plus best supportive care or panitumumab plus best supportive care appears to have statistically significant advantages over treatment with best supportive care alone in patients with KRAS WT status. For the economic evaluation, five studies met the inclusion criteria. The base-case incremental cost-effectiveness ratio (ICER) for KRAS WT patients for cetuximab compared with best supportive care is £98,000 per quality-adjusted life-year (QALY), for panitumumab compared with best supportive care is £150,000 per QALY and for cetuximab plus irinotecan compared with best supportive care is £88,000 per QALY. All ICERs are sensitive to treatment duration.In the specific populations of interest, there is a lack of evidence on bevacizumab, cetuximab and cetuximab plus irinotecan used second line and on bevacizumab and cetuximab plus irinotecan used third line. For cetuximab plus irinotecan treatment for KRAS WT people, there is no direct evidence on progression-free survival, overall survival and duration of treatment.Although cetuximab and panitumumab appear to be clinically beneficial for KRAS WT patients compared with best supportive care, they are likely to represent poor value for money when judged by cost-effectiveness criteria currently used in the UK. It would be useful to conduct a RCT for patients with KRAS WT status receiving cetuximab plus irinotecan.The National Institute for Health Research Health Technology Assessment programme." @default.
• W1994271665 created "2016-06-24" @default.
• W1994271665 creator A5034168180 @default.
• W1994271665 creator A5037428320 @default.
• W1994271665 creator A5061681421 @default.
• W1994271665 creator A5067817683 @default.
• W1994271665 creator A5068818875 @default.
• W1994271665 creator A5081409332 @default.
• W1994271665 creator A5082727271 @default.
• W1994271665 creator A5089453687 @default.
• W1994271665 date "2013-04-01" @default.
• W1994271665 modified "2023-09-24" @default.
• W1994271665 title "The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model" @default.
• W1994271665 cites W1573155455 @default.
• W1994271665 cites W1775605021 @default.
• W1994271665 cites W1967470942 @default.
• W1994271665 cites W1979044834 @default.
• W1994271665 cites W1982174962 @default.
• W1994271665 cites W2003984225 @default.
• W1994271665 cites W2005947177 @default.
• W1994271665 cites W2017005150 @default.
• W1994271665 cites W2021566086 @default.
• W1994271665 cites W2028045370 @default.
• W1994271665 cites W2029391326 @default.
• W1994271665 cites W2029883816 @default.
• W1994271665 cites W2042450112 @default.
• W1994271665 cites W2052643694 @default.
• W1994271665 cites W2059489931 @default.
• W1994271665 cites W2067691287 @default.
• W1994271665 cites W2072508272 @default.
• W1994271665 cites W2083774542 @default.
• W1994271665 cites W2086091931 @default.
• W1994271665 cites W2096122707 @default.
• W1994271665 cites W2097121246 @default.
• W1994271665 cites W2098223440 @default.
• W1994271665 cites W2101144899 @default.
• W1994271665 cites W2101858269 @default.
• W1994271665 cites W2106314180 @default.
• W1994271665 cites W2106789440 @default.
• W1994271665 cites W2110108978 @default.
• W1994271665 cites W2110860588 @default.
• W1994271665 cites W2120490763 @default.
• W1994271665 cites W2125447919 @default.
• W1994271665 cites W2131371081 @default.
• W1994271665 cites W2131779687 @default.
• W1994271665 cites W2139248078 @default.
• W1994271665 cites W2140510616 @default.
• W1994271665 cites W2142564546 @default.
• W1994271665 cites W2143743735 @default.
• W1994271665 cites W2146100972 @default.
• W1994271665 cites W2147718573 @default.
• W1994271665 cites W2155311724 @default.
• W1994271665 cites W2156575195 @default.
• W1994271665 cites W2156700619 @default.
• W1994271665 cites W2157416388 @default.
• W1994271665 cites W2157769714 @default.
• W1994271665 cites W2160577249 @default.
• W1994271665 cites W2165132869 @default.
• W1994271665 cites W2170655985 @default.
• W1994271665 cites W2171790106 @default.
• W1994271665 cites W2245406219 @default.
• W1994271665 cites W2246750959 @default.
• W1994271665 cites W2266278872 @default.
• W1994271665 cites W2330814896 @default.
• W1994271665 cites W2460783501 @default.
• W1994271665 cites W2590010214 @default.
• W1994271665 cites W3151002452 @default.
• W1994271665 cites W2115790682 @default.
• W1994271665 doi "https://doi.org/10.3310/hta17140" @default.
• W1994271665 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4781495" @default.
• W1994271665 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23547747" @default.
• W1994271665 hasPublicationYear "2013" @default.
• W1994271665 type Work @default.
• W1994271665 sameAs 1994271665 @default.
• W1994271665 citedByCount "61" @default.
• W1994271665 countsByYear W19942716652013 @default.
• W1994271665 countsByYear W19942716652014 @default.
• W1994271665 countsByYear W19942716652015 @default.
• W1994271665 countsByYear W19942716652016 @default.
• W1994271665 countsByYear W19942716652017 @default.
• W1994271665 countsByYear W19942716652018 @default.
• W1994271665 countsByYear W19942716652019 @default.
• W1994271665 countsByYear W19942716652020 @default.
• W1994271665 countsByYear W19942716652021 @default.
• W1994271665 countsByYear W19942716652022 @default.
• W1994271665 countsByYear W19942716652023 @default.
• W1994271665 crossrefType "journal-article" @default.
• W1994271665 hasAuthorship W1994271665A5034168180 @default.
• W1994271665 hasAuthorship W1994271665A5037428320 @default.
• W1994271665 hasAuthorship W1994271665A5061681421 @default.
• W1994271665 hasAuthorship W1994271665A5067817683 @default.
• W1994271665 hasAuthorship W1994271665A5068818875 @default.
• W1994271665 hasAuthorship W1994271665A5081409332 @default.
• W1994271665 hasAuthorship W1994271665A5082727271 @default.
• W1994271665 hasAuthorship W1994271665A5089453687 @default.
• W1994271665 hasBestOaLocation W19942716651 @default.
• W1994271665 hasConcept C121608353 @default.
• W1994271665 hasConcept C126322002 @default.
• W1994271665 hasConcept C143998085 @default.
• W1994271665 hasConcept C2776694085 @default.

• next